Content area

|
|

Antitrombotisk behandling af patienter med valvulær atrieflimren

Forfatter(e)
Ann Bovin1, Thomas Decker Christensen2, 3 & Erik Lerkevang Grove3, 4 1) Hjertesygdomme, Hospitalsenheden Vest, Herning 2) Hjerte-, Lunge- og Karkirurgi, Aarhus Universitetshospital 3) Institut for Klinisk Medicin, Aarhus Universitet 4) Hjertesygdomme, Aarhus Universitetshospital Ugeskr Læger 2017;179:V02170156
Reference: 
Ugeskr Læger 2017;179:V02170156
Blad nummer: 
Sidetal: 
2-6
Antithrombotic treatment of patients with valvular atrial fibrillation
Atrial fibrillation (AF) is associated with a markedly increased risk of thromboembolic events, particularly in patients with valvular AF. Recent trials comparing vitamin K antagonists with non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF excluded most patients with valvular AF. Although the definition of valvular AF is disputed, the lack of evidence regarding the use of NOACs for these patients is not. We discuss the definition of valvular AF, the risk of thromboembolism, and the antithrombotic treatment for stroke prevention in these patients.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Skøt Hindrup | 18/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer
af Karin Marlen Moldrup | 13/04
3 kommentarer
af Merete Stampe Mølberg | 13/04
7 kommentarer